Heron Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on Heron Therapeutics Inc in one report.
- Save hours of research time and resources with
our up-to-date Heron Therapeutics Inc Strategy Report
- Understand Heron Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Heron Therapeutics Inc (Heron) is a biotechnology company that uses proprietary polymer-based drug delivery platform to develop novel, patient-focused drugs for patients suffering from various types of cancer and pain. Its proprietary Biochronomer technology is a polymer-based drug delivery platform, that improves the therapeutic profile of injectable pharmaceuticals. The company's marketed products include Sustol, an extended-release injection indicated in combination with other antiemetics in adults for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy (MEC); Cinvanti for chemotherapy-induced nausea and vomiting (CINV) prevention and Zynrelef (HTX-011) for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults. Heron is headquartered in San Diego, California, the US.
Heron Therapeutics Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
SustolL: | Cinvanti |
Chemotherapy-Induced Nausea and Vomiting | Sustol |
Acute and Delayed Nausea and Vomiting associated with Initial and Repeat Courses of Moderately Emetogenic Chemotherapy | Zynrelef |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Regulatory Approval | In January, the company secured approval from the U.S. Food and Drug Administration for its supplemental New Drug Application for ZYNRELEF (bupivacaine and meloxicam) extended-release solution. |
2024 | Contracts/Agreements | In January, the company entered into a partnership with CrossLink Life Sciences to enlarge ZYNRELEF promotion for orthopedic indications. |
2023 | Regulatory Approval | In March, the company announced that CMS approved transitional pass-through status for APONVIE (aprepitant) injectable emulsion. |
Competitor Comparison
Key Parameters | Heron Therapeutics Inc | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc | GSK plc |
---|---|---|---|---|---|
Headquarters | United States of America | Switzerland | United States of America | United States of America | United Kingdom |
City | San Diego | Basel | Kenilworth | New York | Brentford |
State/Province | California | - | New Jersey | New York | England |
No. of Employees | 126 | 103,605 | 72,000 | 88,000 | 70,212 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Adam Morgan | Chairman | Executive Board | 2023 | - |
Craig Collard | Chief Executive Officer; Director | Executive Board | 2023 | - |
Chris Storgard, M.D. | Chief Medical Officer | Senior Management | 2019 | 57 |
Thomas B. Ottoboni, Ph.D. | Senior Vice President - Pharmaceutical and Translational Sciences; Chief Scientific Officer | Senior Management | 2019 | 64 |
William Forbes | Executive Vice President; Chief Development Officer | Senior Management | 2023 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer